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Clozapine treatment for 
schizophrenia-related 
polydipsia
Tratamento com clozapina 
da polidipsia relacionada à 
esquizofrenia
AB was a 33 year-old man with a history of 15 years of 
hebephrenic schizophrenia and no previous history of psychogenic 
polydipsia according to the reports of relatives and care takers. He 
was admitted to our clinic due to episodes of agitation and vomiting, 
as reported by a nurse from the institution where the patient lives. 
He had been on olanzapine 20mg per day and haloperidol 10mg 
per day for the previous three months. At admission, he presented 
a BPRS score of 39 points and PANSS scores of 61 in the general 
psychopathology scale, 15 in the positive scale, and 47 in the 
negative scale. During his stay, we observed that episodes of agitation 
and vomiting initiated after exaggerated water intake. At one point, 
the patient’s sodium serum level reached 130mg/dL (normal range: 
135-155). Attempts to keep the patient from taking water resulted 
in severe agitation requiring pharmacological interventions to avoid 
aggressiveness. AB also presented severe akathisia refractory to 
treatment with benzodiazepines and anticholinergics. In a previous 
hospitalization at the same clinic, the patient presented akathisia 
while on olanzapine monotherapy, with no further worsening after 
the addition of haloperidol, according to chart reports.   
Haloperidol was tittered down and, after its suspension olanzapine 
was tittered down while clozapine was started and tittered up at a rate 
of 25mg every two days. AB presented with a marked improvement 
of both psychogenic polydipsia and akathisia with dosages as low as 
100mg per day of clozapine. At 150mg per day of clozapine, BPRS 
scores had decreased to 23 and PANSS scores to 38, 9, and 32 in the 
general psychopathology, positive scale, and negative scale, respectively.
This case report gives further support to the use of clozapine 
when psychogenic polydipsia evolves in schizophrenic patients. It 
is possible that the quinpirole-induced polydipsia does not mimic 
Dear Editor,
Psychogenic polydipsia occurs in 2-3% of patients with schizophrenia 
and may lead to severe clinical complications such as hyponatremia, 
convulsions, and death. Despite its potential morbidity, polydipsia in 
schizophrenic patients has not been the subject of controlled clinical 
investigations to date. As a result, treatment options for this condition 
are scarce and the evidence on their efficacy is weak.1,2 
Clozapine has been proposed as a possible therapeutic alternative 
based on a few case reports.1 However, in a recent study investigating 
the effects of clozapine and haloperidol in an animal model of 
psychogenic polydipsia induced by quinpirole, haloperidol showed 
superior efficacy in reverting polydipsia.3
Contrasting with the finding based on the animal model, we describe 
the case of a patient who developed psychogenic polydipsia while in use 
of haloperidol and olanzapine and who had a marked improvement 
of these symptoms after clozapine was initiated.
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what happens in schizophrenic patients suffering from polydipsia. 
Therefore, controlled clinical investigations evaluating the effects 
of clozapine in the treatment of polydipsia are still warranted. 
Juliana Belo Diniz, Quirino Cordeiro
Department and Institute of Psychiatry, Universidade de São 
Paulo (USP) Medical School, São Paulo, SP, Brazil
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